# The FDA has proposed removing popular weight-loss drugs from a key compounding list.

*biotech · news · 2026-04-30 · Devdiscourse*

## Key points

- The FDA proposes removing semaglutide and tirzepatide from a key compounding list.
- Outsourcing facilities (503B) may face restrictions on producing these weight-loss drug compounds.
- Telehealth companies using 503A pharmacies, like Hims & Hers, are not directly impacted by the proposal.
- U.S.-listed shares of Novo Nordisk and Eli Lilly rose sharply following the FDA's announcement.
- The FDA will accept public comments on this proposal until June 29.

**Companies:** Eli Lilly, Novo Nordisk, Hims & Hers
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3892861-fdas-proposal-to-exclude-novo-and-lilly-weight-loss-drugs-from-compounding-list)

---

Canonical: https://newsio.io/n/bb595abe-b8d9-49d8-a597-ac2ac0c853c7/the-fda-has-proposed-removing-popular-weight-loss-drugs-from-a-key-compounding-l
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works